Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 750
- Registration Number
- NCT00002701
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹Federico II University Medical School, Naples (Napoli), Italy
🇮🇹Ospedale S. Gennora USL 42, Naples (Napoli), Italy
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-10
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT00002658
- Locations
- 🇬🇧
University of Wales College of Medicine, Cardiff, Wales, United Kingdom
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Riverside Haematology Group
- Target Recruit Count
- 400
- Registration Number
- NCT00003602
- Locations
- 🇬🇧
Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Leukemia Research Fund
- Target Recruit Count
- 2000
- Registration Number
- NCT00005823
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom
🇬🇧University College Hospital, London, England, United Kingdom
🇬🇧Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- III. Medizinische Klinik Mannheim
- Target Recruit Count
- 1000
- Registration Number
- NCT00025402
- Locations
- 🇩🇪
Tumorzentrum Berlin-Moabit, Berlin, Germany
🇩🇪Wenckebach - Krankenhaus, Berlin, Germany
🇩🇪Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany
Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- West of Scotland Lymphoma Group
- Target Recruit Count
- 200
- Registration Number
- NCT00006232
- Locations
- 🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧Centre for Cancer Research and Cell Biology at Belfast City Hospital, Belfast, Northern Ireland, United Kingdom
🇬🇧Vale Of Leven D G Hospital, Alexandria, Scotland, United Kingdom
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-08-27
- Target Recruit Count
- 472
- Registration Number
- NCT00052299
- Locations
- 🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇳🇱Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇦🇹A. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung, Linz, Austria
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00023920
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00016159
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Childhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Monoblastic Leukemia (M5a)Childhood Acute Monocytic Leukemia (M5b)Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Childhood Acute Myelomonocytic Leukemia (M4)Childhood Myelodysplastic SyndromesChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndromes
- Interventions
- Drug: daunorubicin hydrochlorideDrug: asparaginaseDrug: therapeutic hydrocortisoneRadiation: 3-dimensional conformal radiation therapyDrug: fludarabine phosphateProcedure: allogeneic bone marrow transplantationBiological: filgrastimDrug: cytarabineDrug: idarubicinDrug: dexamethasoneBiological: aldesleukinDrug: thioguanineDrug: etoposideDrug: methotrexateDrug: cyclophosphamideDrug: busulfan
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 880
- Registration Number
- NCT00002798
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.